Parathyroid Adenoma Clinical Trial
— 18FCHOfficial title:
Evaluation of Patients With Suspected Parathyroid Adenoma and Negative or Equivocal 99mTc Sestamibi SPECT/CT Using 18F Fluorocholine PET/CT
This study proposes the use of a well-established PET isotope, Fluorine-18 (18F), bound to Choline, for a prospective single-center, single-arm study for participants with suspected parathyroid adenoma and negative or equivocal standard of care 99mTc Sestamibi SPECT/CT
Status | Recruiting |
Enrollment | 100 |
Est. completion date | July 1, 2027 |
Est. primary completion date | July 1, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Suspected parathyroid adenoma (elevated serum calcium and inappropriately normal or high levels of parathyroid hormone) 2. Negative or equivocal 99mTc Sestamibi SPECT/CT 3. Able to provide written consent 4. Total bilirubin = 1.5 x upper limit of normal (ULN) 5. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) = 5 xULN 6. Karnofsky performance status of >50 (or ECOG/WHO equivalent) 7. Women must not be pregnant per the Department of Radiology Policy on Imaging in Potentially Pregnant and Pregnant Women. Exclusion Criteria: 1. Less than 18 years old at the time of radiotracer administration 2. Creatinine clearance (calculated using Cockcroft-Gault formula, or measured) < 60 mL/min or serum creatinine >1.5 x ULN 3. QTcF >470 msec on electrocardiogram (ECG) or congenital long QT syndrome |
Country | Name | City | State |
---|---|---|---|
United States | Stanford Hospital and Clinics | Stanford | California |
Lead Sponsor | Collaborator |
---|---|
Andrei Iagaru |
United States,
Ciappuccini R, Morera J, Pascal P, Rame JP, Heutte N, Aide N, Babin E, Reznik Y, Bardet S. Dual-phase 99mTc sestamibi scintigraphy with neck and thorax SPECT/CT in primary hyperparathyroidism: a single-institution experience. Clin Nucl Med. 2012 Mar;37(3):223-8. doi: 10.1097/RLU.0b013e31823362e5. — View Citation
DeGrado TR, Reiman RE, Price DT, Wang S, Coleman RE. Pharmacokinetics and radiation dosimetry of 18F-fluorocholine. J Nucl Med. 2002 Jan;43(1):92-6. Erratum In: J Nucl Med 2002 Apr;43(4):509. — View Citation
Graves CE, Hope TA, Kim J, Pampaloni MH, Kluijfhout W, Seib CD, Gosnell JE, Shen WT, Roman SA, Sosa JA, Duh QY, Suh I. Superior sensitivity of 18F-fluorocholine: PET localization in primary hyperparathyroidism. Surgery. 2022 Jan;171(1):47-54. doi: 10.1016/j.surg.2021.05.056. Epub 2021 Jul 21. — View Citation
Hope TA, Graves CE, Calais J, Ehman EC, Johnson GB, Thompson D, Aslam M, Duh QY, Gosnell JE, Shen WT, Roman SA, Sosa JA, Kluijfhout WP, Seib CD, Villaneuva-Meyer JE, Pampaloni MH, Suh I. Accuracy of 18F-Fluorocholine PET for the Detection of Parathyroid Adenomas: Prospective Single-Center Study. J Nucl Med. 2021 Nov;62(11):1511-1516. doi: 10.2967/jnumed.120.256735. Epub 2021 Mar 5. — View Citation
Kluijfhout WP, Pasternak JD, Gosnell JE, Shen WT, Duh QY, Vriens MR, de Keizer B, Hope TA, Glastonbury CM, Pampaloni MH, Suh I. 18F Fluorocholine PET/MR Imaging in Patients with Primary Hyperparathyroidism and Inconclusive Conventional Imaging: A Prospective Pilot Study. Radiology. 2017 Aug;284(2):460-467. doi: 10.1148/radiol.2016160768. Epub 2017 Jan 25. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of lesions detected by PET/CT for detecting parathyroid adenomas. | Inclusion criteria suggest recruiting patients with negative or equivocal SPECT/CT, so based on this there will be 0 lesions on SPECT/CT. The goal is to compare/count the number of lesions from PET/CT, if any present versus no lesions with SPECT/CT | up to 1 hour |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT04085913 -
Exparel Injection Effect on Postoperative Opioid Usage
|
Early Phase 1 | |
Completed |
NCT04040946 -
Trial Comparing 2 Diagnostic Strategies for Preoperative Localization of Parathyroid Adenoma in Primary Hyperparathyroidism:TEMP / CT With Tc99m-sestaMIBI or PET / CT With F18-choline in First Intention
|
Phase 3 | |
Completed |
NCT04344886 -
Optimization and Individualization of Diagnostic Scintigraphy Protocol and Minimally Invasive Radio-guided Parathyroid Surgery
|
N/A | |
Completed |
NCT03469310 -
Minimizing Narcotic Analgesics After Endocrine Surgery
|
Phase 4 | |
Not yet recruiting |
NCT01084356 -
Evaluation of a New CZT System
|
N/A | |
Completed |
NCT04299425 -
Evaluating Impact of NIRAF Detection for Identifying Parathyroid Glands During Parathyroidectomy
|
N/A | |
Completed |
NCT04905641 -
The Feasibility of Bilateral Intermediate Cervical Plexus Block for Thyroidectomy/Parathyroidectomy
|
||
Completed |
NCT03027557 -
Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet.
|
Phase 3 | |
Withdrawn |
NCT03516747 -
Preoperational Fine Needle Aspiration of Pathological Parathyroid Gland
|
N/A | |
Recruiting |
NCT05152927 -
Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy
|
N/A | |
Completed |
NCT04570033 -
The Utility of 18F-fluorocholine PET/CT in the Imaging of Parathyroid Adenomas
|
N/A | |
Recruiting |
NCT05022641 -
Evaluating Impact of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy
|
N/A | |
Withdrawn |
NCT02381925 -
Multicenter Registry Comparing Preoperative Imaging for Primary Hyperparathyroidism
|
N/A |